Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 10/2021

01-10-2021 | Parkinson's Disease | Review Article

Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson’s disease—a meta-analysis

Authors: Yanying Yin, Yang Liu, Meisong Xu, XiaoMin Zhang, Chen Li

Published in: Neurological Sciences | Issue 10/2021

Login to get access

Abstract

Background and purpose

Polymorphisms of the catechol-O-methyl transferase (COMT) or monoamine oxidase B (MAO-B) genes may affect the occurrence of dyskinesia in Parkinson’s disease (PD) patients. However, the findings are inconsistent. Thus, we performed a meta-analysis to assess whether COMT and MAO-B genetic variants are associated with an increased incidence of levodopa-induced dyskinesia (LID) in PD patients.

Methods

A literature search of PubMed, Embase, and Cochrane Library was conducted to identify relevant studies published up to January 2021. The strength of the association between the polymorphisms and LID susceptibility was estimated by odds ratio (OR) and associated 95% confidence interval (CI). The pooled ORs were assessed in different genetic models.

Results

Ten studies involving 2385 PD patients were included in the meta-analysis. Analysis of pooled ORs and 95% CIs suggested that the AA genotype of COMT(rs4680) was associated with LID (OR = 1.39, 95%CI: 1.02–1.89, P = 0.039) in the recessive model, and this correlation was more obvious in Brazilian samples in the analysis stratified by ethnicity. For the AG genotype of MAO-B(rs1799836), the pooled OR was 1.66 (95% CI: 1.04–2.65, P = 0.03) in patients with LID versus those without LID in the heterozygote model.

Conclusions

Our meta-analysis implicates the AA genotype of the COMT rs4680 polymorphism as potentially increasing the risk of LID in a recessive genetic model for PD patients. Furthermore, the AG genotype of the MAO-B rs1799836 polymorphism may influence the prevalence of LID in PD patients in the heterozygote model. However, further well-designed studies with larger PD patient cohorts are required to validate these results after adjusting for confounding factors.
Literature
1.
2.
Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 16(8):1239–1252PubMedPubMedCentralCrossRef
3.
4.
Péchevis M, Clarke CE, Vieregge P et al (2005) Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12(12):956–963PubMedCrossRef
5.
Tran TN, Vo TNN, Frei K, Truong DD (2018) Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm 125(8):1109–1117PubMedCrossRef
6.
Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508PubMedCrossRef
7.
Eusebi P, Romoli M, Paoletti FP, Tambasco N, Calabresi P, Parnetti L (2018) Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort. NPJ Parkinsons Dis 4:33PubMedPubMedCentralCrossRef
8.
Strong JA, Dalvi A, Revilla FJ et al (2006) Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 21(5):654–659PubMedCrossRef
9.
Rieck M, Schumacher-Schuh AF, Altmann V et al (2012) DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics 13(15):1701–1710PubMedCrossRef
10.
Lee JY, Cho J, Lee EK, Park SS, Jeon BS (2011) Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord 26(1):73–79PubMedCrossRef
11.
Talkowski ME, McCann KL, Chen M et al (2010) Fine-mapping reveals novel alternative splicing of the dopamine transporter. Am J Med Genet Part B Neuropsychiatr Genet 153B(8):1434–1447CrossRef
12.
Kaiser R, Hofer A, Grapengiesser A (2003) L -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60(11):1750–1755PubMedCrossRef
13.
Watanabe M, Harada S, Nakamura T et al (2003) Association between catechol-O-methyltrans ferase gene polymorphisms and wearing-off and dyskinesia in Parkinson’s disease. Neuropsychobiology 48(4):190–193PubMedCrossRef
14.
Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A (2005) Genetic polymorphism of catechol-O-methyltrans ferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson’s disease. Mov Disord 20(6):734–739PubMedCrossRef
15.
Torkaman-Boutorabi A, Shahidi GA, Choopani S et al (2012) The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson’s disease. Acta Neurobiol Exp (Wars) 72(3):272–82
16.
Hao H, Shao M, An J et al (2014) Association of catechol-O-methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson’s disease in a Chinese population. Parkinsonism Relat Disord 20(10):1041–1045PubMedCrossRef
17.
Cheshire P, Bertram K, Ling H et al (2013) Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis 13(1):24–28PubMedCrossRef
18.
Xiao Q, Qian Y, Liu J, Xu S, Yang X (2017) Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s disease. Transl Neurodegener 6:11PubMedPubMedCentralCrossRef
19.
Sampaio TF, Dos Santos EUD, de Lima GDC et al (2018) MAO-B and COMT genetic variations associated with levodopa treatment response in patients with Parkinson’s disease. J Clin Pharmacol 58(7):920–926PubMedCrossRef
20.
Kakinuma S, Beppu M, Sawai S et al (2020) Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson’s disease. eNeurologicalSci 19:100239PubMedPubMedCentralCrossRef
21.
Dos Santos EUD, da Silva IIFG, Asano AGC, Asano NMJ, De MascenaDiniz Maia M, de Souza PRE (2020) Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson’s disease patients: a population-based cohort study. Mol Biol Rep 47(11):8997–9004PubMedCrossRef
22.
Zhao C, Wang Y, Zhang B, Yue Y, Zhang J (2020) Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson’s disease. Sci Rep 10(1):9521PubMedPubMedCentralCrossRef
23.
Białecka M, Droździk M, Kłodowska-Duda G et al (2004) The effect of monoamine oxidase B (MAOB) and catechol-O- methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson’s disease. Acta Neurol Scand 110(4):260–266PubMedCrossRef
24.
Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M (2008) The association of functional catechol-O- methyltransferase haplotypes with risk of Parkinsons disease, levodopa treatment response, and complications. Pharmacogenet Genomics 18(9):815–821PubMedCrossRef
25.
de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27(1):132–135PubMedCrossRef
26.
27.
Ivanova SA, Alifirova VM, Pozhidaev IV et al (2018) Polymorphisms of catechol-O-methyl transferase (COMT) gene in vulnerability to levodopa-induced dyskinesia. J Pharm Pharm Sci 21(1):340–346PubMedCrossRef
28.
Redenšek S, Flisar D, Kojović M et al (2019) Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson’s disease. Front Pharmacol 10:8PubMedPubMedCentralCrossRef
29.
Michałowska M, Chalimoniuk M, Jówko E et al (2020) Gene polymorphisms and motor levodopa-induced complications in Parkinson’s disease. Brain Behav 10(3):e01537PubMedPubMedCentralCrossRef
30.
Yin B, Chen Y, Zhang L (2014) Association between catechol-O-methyltransferase (COMT) gene polymorphisms, Parkinson’s disease, and levodopa efficacy. Mol Diagnosis Ther 18:253–260CrossRef
31.
Falla M, Di Fonzo A, Hicks AA, Pramstaller PP, Fabbrini G (2021) Genetic variants in levodopa-induced dyskinesia (LID): a systematic review and meta-analysis. Parkinsonism Relat Disord 84:52–60PubMedCrossRef
32.
Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J (2005) A method for meta-analysis of molecular association studies. Stat Med 24(9):1291–1306PubMedCrossRef
33.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef
34.
Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. Br Med J 315(7121):1533–1537CrossRef
35.
Chen J, Lipska BK, Halim N et al (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75(5):807–821PubMedPubMedCentralCrossRef
36.
de la Fuente-Fernández R, Sossi V, Huang Z et al (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127(Pt 12):2747–2754PubMedCrossRef
37.
Garpenstrand H, Ekblom J, Forslund K, Rylander G, Oreland L (2000) Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm (Vienna) 107(5):523–30CrossRef
38.
Costa-Mallen P, Afsharinejad Z, Kelada SN et al (2004) DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson’s disease cases and unrelated controls. Mov Disord 19(1):76–83PubMedCrossRef
39.
Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E (2002) Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 110(1):1–7PubMedCrossRef
40.
Young WF Jr, Laws ER Jr, Sharbrough FW, Weinshilboum RM (1986) Human monoamine oxidase. Lack of brain and platelet correlation. Arch Gen Psychiatry 43(6):604–9PubMedCrossRef
41.
Talati R, Reinhart K, Baker W, White CM, Coleman CI (2009) Pharmacologic treatment of advanced Parkinson’s disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Park Relat Disord 15(7):500–505CrossRef
Metadata
Title
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson’s disease—a meta-analysis
Authors
Yanying Yin
Yang Liu
Meisong Xu
XiaoMin Zhang
Chen Li
Publication date
01-10-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 10/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05509-3

Other articles of this Issue 10/2021

Neurological Sciences 10/2021 Go to the issue

Original Article

Insertable cardiac monitors for detection of atrial fibrillation after cryptogenic stroke: a meta-analysis

Original Article

Headache Gauge: a real-life calendar-based tool for headache monitoring

Correction

Correction to: Shear wave elastography characteristics of upper limb muscle in rigidity-dominant Parkinson’s disease

Review Article

Efficacy of low-level laser therapy in nerve injury repair—a new era in therapeutic agents and regenerative treatments

Brief Communication

ADEM post-Sars-CoV-2 infection in a pediatric patient with Fisher-Evans syndrome

Review Article

Advances in hyperekplexia and other startle syndromes